Abstract
To evaluate the cost-consequences of the investment for anti-Hepatitis C Virus (HCV) treatment by the Italian National Health System (NHS) for patients that will be newly diagnosed through active HCV screening, implemented in Italy starting from 2020.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
